Literature DB >> 28109034

Early detection of pulmonary hypertension in primary myelofibrosis: The role of echocardiography, cardiopulmonary exercise testing, and biomarkers.

Mariarita Sciumè1, Veronica Mattiello1, Daniele Cattaneo1, Cristina Bucelli1, Nicola Orofino1, Lisa Gandolfi1, Loredana Pettine1, Silvia Lonati1, Umberto Gianelli2, Alberto Pierini3, Agostino Cortelezzi1, Alessandra Iurlo1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28109034     DOI: 10.1002/ajh.24656

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

1.  Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.

Authors:  Matthew Austin; Peter J Quesenberry; Corey E Ventetuolo; Olin Liang; John L Reagan
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-05-13

2.  Exercise-Induced Pulmonary Hypertension Is Associated with High Cardiovascular Risk in Patients with HIV.

Authors:  Rosalinda Madonna; Silvia Fabiani; Riccardo Morganti; Arianna Forniti; Filippo Biondi; Lorenzo Ridolfi; Riccardo Iapoce; Francesco Menichetti; Raffaele De Caterina
Journal:  J Clin Med       Date:  2022-04-27       Impact factor: 4.964

3.  Transforming growth factor β-mediated micromechanics modulates disease progression in primary myelofibrosis.

Authors:  Patric Teodorescu; Sergiu Pasca; Ancuta Jurj; Grigore Gafencu; Jon-Petur Joelsson; Sonia Selicean; Cristian Moldovan; Raluca Munteanu; Anca Onaciu; Adrian-Bogdan Tigu; Mihail Buse; Alina-Andreea Zimta; Rares Stiufiuc; Bobe Petrushev; Minodora Desmirean; Delia Dima; Cristina Vlad; Jon Thor Bergthorsson; Cristian Berce; Stefan Ciurea; Gabriel Ghiaur; Ciprian Tomuleasa
Journal:  J Cell Mol Med       Date:  2020-09-05       Impact factor: 5.310

4.  The value of cardiopulmonary exercise testing in the diagnosis of pulmonary hypertension.

Authors:  Qin Luo; Xue Yu; Zhihui Zhao; Qing Zhao; Xiuping Ma; Qi Jin; Lu Yan; Yi Zhang; Zhihong Liu
Journal:  J Thorac Dis       Date:  2021-01       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.